This subgroup analysis of SUSTAIN-3 (n=96) studies patients with treatment-resistant depression (TRD) who received a second induction and maintenance treatment with esketamine nasal spray (ESK) plus oral antidepressant (AD) after a relapse in SUSTAIN-1.
Background
Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK plus oral antidepressant (AD) after a relapse in SUSTAIN-1.
Methods
Patients aged 18-64 years who achieved stable remission or response with ESK and subsequently relapsed after randomization to continue ESK or switch to placebo nasal spray (PBO) in SUSTAIN-1 and entered the IND phase of SUSTAIN-3 were included in this interim analysis. Response (≥50% improvement in total score from baseline for Montgomery-Åsberg Depression Rating Scale [MADRS] and Patient Health Questionnaire 9-item [PHQ-9]), remission (MADRS score ≤12; PHQ-9 total score <5), changes in depression rating scores (measured as mean change from baseline), and safety were evaluated (incidence of treatment-emergent and serious adverse events [AE]).
Results
Of the 96 eligible patients who entered IND in SUSTAIN-3, 32 (33.3%) were taking ESK+AD at the time of relapse in SUSTAIN-1 and 64 (66.7%) were taking AD+PBO. Substantial improvements in depressive symptoms were observed over the second IND phase in both groups and were maintained over the optimization/maintenance (OP/M) phase. MADRS response rates following a second IND were 71.9% and 73.4% for previously relapsed (PR) ESK+AD and PR-AD+PBO, respectively; remission rates were 62.5% and 60.9%, respectively. During the IND and OP/M phases, 58.3% and 83.3% of patients experienced a treatment-emergent AE, respectively. No patients discontinued due to an AE during the second IND.
Conclusions
Patients with TRD benefitted from receiving a second IND and maintenance treatment with ESK and no new safety signals were identified.
Women have about a twofold greater lifetime risk of major depressive disorder than men and often differ from men in clinical presentation, comorbidities, age at onset, episode duration, and treatment response. Previous studies have reported inconsistent sex differences in antidepressant efficacy and tolerability, and factors such as reproductive lifecycle stage, use of hormone therapy, neuronal circuitry, and drug metabolism have been proposed as contributors. Esketamine, the S-enantiomer of ketamine and an NMDA receptor antagonist, is approved in several jurisdictions for treatment-resistant depression (TRD) in conjunction with an oral antidepressant; its pivotal Phase 2 and Phase 3 trials provide a dataset suitable for secondary analyses of sex effects. Jones and colleagues undertook a post hoc analysis of three short-term Phase 3 trials (TRANSFORM-1, TRANSFORM-2, TRANSFORM-3) to assess whether efficacy and safety of esketamine nasal spray differ between women and men with TRD. The primary aims were to compare improvement in depressive symptoms, comorbid anxiety, and response and remission rates by sex; secondary aims focused on whether menopausal status or use of hormonal therapy among women influenced these outcomes and whether clinical factors distinguished responders from non-responders.
The analysis uses data from three Phase 3, double-blind, active-controlled, multicentre trials (TRANSFORM-1, TRANSFORM-2, TRANSFORM-3) conducted between August 2015 and February 2018. Each study comprised a 4-week screening/prospective observational phase to assess response to the patient’s current antidepressant(s), a 4-week double-blind treatment phase in which non-responders were randomised to twice-weekly esketamine nasal spray or matching placebo nasal spray plus a newly initiated daily oral antidepressant (SSRI or SNRI), and a post-treatment safety follow-up (up to 24 weeks for TRANSFORM-1/2 and 2 weeks for TRANSFORM-3). At randomisation participants met criteria for TRD, defined as non-response to at least two prior oral antidepressants in the current episode. Key exclusions included recent suicidal intent or behaviour, psychotic or bipolar disorders, recent moderate/severe substance use disorder, and positive drug screens. Dosing differed by study: TRANSFORM-1 used fixed esketamine doses of 56 mg and 84 mg; TRANSFORM-2 used flexible dosing of 56 mg and 84 mg; TRANSFORM-3 (older adults ≥65 years) included 28 mg, 56 mg, and 84 mg options. Independent, blinded raters assessed depressive symptoms with the Montgomery–Åsberg Depression Rating Scale (MADRS) at baseline and during treatment. Patient-reported measures included the Sheehan Disability Scale (SDS), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7; assessed in TRANSFORM-1/2). Reproductive lifecycle status and exogenous hormone use (oral contraceptives, hormone replacement therapy) were prospectively documented using the Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire. Efficacy analyses included all randomised patients who received at least one dose of intranasal study drug and one dose of oral antidepressant; safety analyses included all patients who received at least one dose of either medication. TRANSFORM-1 and TRANSFORM-2 were pooled for primary analyses. The primary endpoint was change from baseline to day 28 in MADRS total score, analysed by sex using a mixed-effects model for repeated measures (MMRM) with baseline score as covariate and fixed effects for treatment, study (for pooled analyses), region, oral antidepressant class, day, sex, and their interactions, plus a random patient effect. SDS and PHQ-9 used similar MMRM models; GAD-7 change used analysis of covariance. Response (≥ 50% reduction in MADRS) and remission (MADRS ≤ 12) at day 28 were analysed by treatment and sex using the Cochran–Mantel–Haenszel test. Adverse events were summarised by frequency by treatment group and sex.
Of 711 randomised patients across the TRANSFORM trials, 702 were included in efficacy analyses (464 women, 66.1%; 238 men, 33.9%) and 705 in safety analyses. Most participants completed double-blind treatment (women 90.7%; men 86.3%). Baseline demographic and clinical characteristics were generally similar between sexes within each study; TRANSFORM-3 enrolled older patients by design. In pooled TRANSFORM-1/2, 71.5% of patients had comorbid anxiety symptoms at baseline, with no sex difference in prevalence. Common medical comorbidities included hypertension, cardiovascular disease, diabetes and thyroid disease, with cardiovascular disease and diabetes more frequent in older men and thyroid disease more common in women. Mean reductions in MADRS total score from baseline to day 28 were greater with esketamine plus oral antidepressant than with oral antidepressant plus placebo for both sexes. In pooled TRANSFORM-1/2 the mean (SD) MADRS change at day 28 was −20.3 (13.19) for women receiving esketamine/antidepressant versus −15.8 (14.67) for women receiving antidepressant/placebo; corresponding values for men were −18.3 (14.08) versus −16.0 (14.30). In TRANSFORM-3 the mean (SD) changes were −9.9 (13.34) versus −6.9 (9.65) for women, and −10.3 (11.96) versus −5.5 (7.64) for men. The analysis did not demonstrate a significant sex effect or treatment-by-sex interaction (p > 0.35). The between-group differences versus antidepressant/placebo for both sex subgroups fell within a range the authors describe as clinically meaningful (approximately 2–3 points). Responder and remission proportions at day 28 were numerically higher with esketamine/antidepressant than with antidepressant/placebo in both women and men. In TRANSFORM-3, remission (but not response) was numerically higher among older women than older men, but small sample sizes limit firm conclusions. By menopausal status in TRANSFORM-1/2, pre-menopausal and post-menopausal women treated with esketamine had similar response rates; peri-menopausal women (n = 25) showed a numerically lower response to esketamine/antidepressant. Hormonal therapy use in TRANSFORM-1/2 was associated with a higher response rate at day 28 in the antidepressant/placebo arm (hormone users 73.7% [14/19] vs non-users 40.3% [48/119]) but not in the esketamine/antidepressant arm (hormone users 54.2% [28/48] vs non-users 62.3% [104/167]). Patient-reported outcomes showed treatment benefit for functioning (SDS) and self-reported depressive symptoms (PHQ-9) for both sexes in pooled TRANSFORM-1/2; analyses for SDS and PHQ-9 did not show significant sex effects or treatment-by-sex interactions (p > 0.20). For GAD-7 there was no treatment-by-sex interaction (p > 0.52), although a sex effect trended toward significance (p = 0.07), indicating greater change from baseline among women regardless of treatment. The most frequent adverse events (incidence > 20% in esketamine recipients) were nausea, dissociation, dizziness and vertigo. Incidences of nausea and dissociation were higher among women than men across ages. Patterns for dizziness and vertigo varied by age subgroup and sex. Increased blood pressure was reported in 9.3% overall and was numerically higher among younger men (12.8%) and older women (17.8%). Most adverse events occurred on dosing days, were mild or moderate, resolved the same day, and were generally not treatment-limiting. Dissociation events had a median duration of about 0.7–1 hour within the post-dose observation period; 3.1% of dissociation events were classified as severe and none were judged serious. Serious adverse events during esketamine treatment were reported for two women (0.7%) and four men (2.9%); one death occurred on day 55 after a road traffic accident that was considered doubtfully related to study drug. Discontinuations due to adverse events occurred in 4.8% (20/415) of esketamine-treated patients versus 1.7% (5/287) of placebo nasal spray recipients; 12 women and 8 men discontinued esketamine prematurely for adverse events.
Jones and colleagues interpret the findings as indicating similar and generally robust antidepressant effects of esketamine nasal spray plus an oral antidepressant in both women and men with TRD over the 4-week double-blind treatment period. Although the magnitude of the between-group difference versus oral antidepressant plus placebo varied numerically by sex across studies (for example, numerically larger in women in pooled TRANSFORM-1/2 and larger in men in TRANSFORM-3), the treatment-by-sex interaction was not statistically significant and confidence intervals overlapped, so the authors do not conclude sex-based differential efficacy. They note the observed between-group differences fall within a range considered clinically meaningful and are consistent with effects seen in trials of recently approved biogenic amine antidepressants compared with placebo. The discussion raises possible explanations for the absence of sex differences, including the lack of sex differences in esketamine pharmacokinetics reported elsewhere, and contrasts the results with inconsistent sex effects reported for other antidepressant classes. The authors highlight findings related to reproductive factors: peri-menopausal women comprised a small subgroup with numerically lower response to esketamine, while post-menopausal women appeared to derive similar benefit to pre-menopausal women; concomitant hormonal therapy increased response in the antidepressant/placebo arm but not in the esketamine arm. Safety findings showed some sex-specific patterns, with higher rates of nausea and dissociation in women and variable patterns for dizziness, vertigo and increased blood pressure by age and sex. The authors relate this to broader evidence that women have higher rates of adverse drug reactions for some medications. Limitations acknowledged by the study team include the post hoc nature of the analyses, lack of stratification by sex at randomisation, higher female participation which nonetheless reflects the epidemiology of depression, small sample sizes for menopausal subgroup and TRANSFORM-3 analyses (the latter also differed in dosing, including a 28 mg option), exclusion of patients with some common comorbidities, and low representation of non-white participants. These factors limit the generalisability of some subgroup findings and warrant cautious interpretation.
These post hoc analyses support the antidepressant efficacy and overall safety of esketamine nasal spray for women with treatment-resistant depression, without notable differential effects based on sex. The authors suggest the findings contribute to data-informed decision-making for women with TRD.
Women compared to men exhibit a twofold higher risk of major depressive disorder (MDD), and differences in clinical presentation and comorbidities. In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study of outpatients with nonpsychotic MDD, women had approximately 2 years earlier onset of their first major episode, greater severity of MDD, and approximately 5.6 months longer duration of depressive episodes, compared to the men. Women were more likely to experience concurrent symptoms consistent with generalized anxiety disorder, somatoform disorder, bulimia, and atypical depression, and less likely to have concurrent obsessive compulsive, alcohol abuse, and drug abuse disorders. Likewise, response to antidepressants can vary between women and men, including differences in time to response, response rate, and adverse effects). Various factors have been suggested to explain disparity in antidepressant response between women and men, including differences in neuronal circuitry, hormone levels, and drug metabolism. For example, menopausal status and sex hormone therapy impacted treatment responses among women receiving selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitor (SNRI) therapy in some studies, but not in others. A more recent study found no difference in efficacy for women compared to men with intravenous ketamine given as an acute treatment in patients with treatment-resistant depression (TRD). These mixed findings underscore the value of investigating if there are sex differences in response to newly approved antidepressants. Esketamine (the S-enantiomer of ketamine racemate), a first-in-class glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist, has been approved by the US Food and Drug Administration, the European Medicines Agency, and multiple other health authorities for TRD, in conjunction with an oral antidepressant (Spravato Prescribing Information 2020; Spravato Summary of Product Characteristics 2020). The approval of esketamine nasal spray was based, in large part, on efficacy and safety findings from phase 2 and phase 3 studies in patients with TRD. The database from these clinical development trials forms the basis for additional investigations that may facilitate clinical management of patients treated with esketamine nasal spray in real world clinical practice. A post hoc analysis of data from three short-term phase 3 studies) was conducted to assess the effect of sex on the efficacy and safety of esketamine nasal spray in patients with TRD. The primary aims of these analyses are to determine whether there are differences between women and men based on improvement of depressive symptoms, comorbid anxiety, and response and remission rates with esketamine. Secondarily, among women, the aims were to determine if the aforementioned outcomes are affected by menopausal status or by use of hormonal therapy and if there are clinical factors that differentiated responders from non-responders, supporting data-informed decision-making for women.
The methods of the TRANSFORM studies are published elsewhere. Study methods salient to the work reported here are summarized below.
Institutional review boards/ethics committees approved the study protocols and their amendments, written consent was obtained from all patients before study participation, and the studies are registered at clinicaltrials.gov (identifiers: NCT02417064, NCT02418585, and NCT02422186).
The TRANSFORM trials were phase 3, double-blind, activecontrolled, multicenter studies of esketamine nasal spray in patients with TRD. The trials comprised three phases: (1) 4-week screening/prospective observational phase assessing treatment response to the current antidepressant(s), (2) 4-week double-blind treatment phase with esketamine or placebo nasal spray combined with a newly initiated oral antidepressant, and (3) post-treatment follow-up phase assessing safety (TRANSFORM-1 and TRANSFORM-2: up to 24 weeks; TRANSFORM-3: 2 weeks). The studies were conducted between August 2015 and February 2018. features, confirmed by the Mini International Neuropsychiatric Inventory (MINI)). At randomization, participants had TRD, defined as non-response to two or more oral antidepressants, taken at an adequate dosage and for an adequate duration, during the current episode. Key exclusion criteria included suicidal ideation with intent to act within the prior 6 months or suicidal behavior within the prior year; diagnosis of psychotic or bipolar disorders; recent history (within prior 6 months) of moderate or severe substance use disorder; and positive test result(s) for specified drugs of abuse. Full lists of the inclusion and exclusion criteria for each study are published.
Patients continued taking their current antidepressant during the 4-week screening/prospective observational phase. At the end of the screening phase, non-responders (≤ 25% improvement in Montgomery-Åsberg Depression Rating Scale [MADRS] total score from week 1 to week 4) discontinued all current antidepressant treatment(s) and were randomized to double-blind treatment, consisting of twiceweekly esketamine nasal spray or matching (appearance, taste, and packaging) placebo nasal spray, each combined with a newly initiated oral antidepressant (SSRI or SNRI) taken daily. The doses of esketamine were 56 mg (starting dose) and 84 mg in the TRANSFORM-1 (fixed dose) and TRANSFORM-2 (flexible dose) studies and 28 mg (starting dose and a dose option during the study), 56 mg, and 84 mg in TRANSFORM-3 (flexible dose).
Improvement in symptoms of depression was assessed by the MADRS, which was administered by independent, blinded raters at baseline and subsequent visits during the double-blind treatment phase. In addition, patient-reported outcomes included an assessment of function using the Sheehan Disability Scale (SDS), depressive symptoms using the Patient Health Questionnaire 9-item (PHQ-9), and severity of anxiety using the Generalized Anxiety Disorder 7-item (GAD-7) Scale (GAD-7 in TRANSFORM-1 and TRANSFORM-2 only). The clinician-rated Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire, Module 1, was used to assess and prospectively document reproductive lifecycle status (pre-menopausal, peri-menopausal, or post-menopausal), history of worsening mood during the luteal phase of the menstrual cycle, length and regularity of menstrual cycles, and use of exogenous hormones, including hormonal oral contraceptives (OC) and hormone replacement therapy (HRT). In reporting menopause status, the investigator selected the appropriate choice from the following: premenopausal; peri-menopausal (irregular periods and/or other symptoms of peri-menopause, such as hot flashes not explained by other reasons); post-menopausal non-surgical (> 12 months of amenorrhea); and post-menopausal surgical (status post bilateral oophorectomy). Treatment-emergent adverse events were assessed throughout the study.
Efficacy was analyzed in a data set that included all randomized patients who received at least 1 dose of intranasal study drug (esketamine or placebo) and 1 dose of oral antidepressant, and adverse events were analyzed in a data set that included all patients that received at least 1 dose of either medication. Data from the TRANSFORM-1 and TRANSFORM-2 studies were pooled. Baseline characteristics and psychiatric history were summarized by sex using descriptive statistics. The prevalence of comorbid anxiety at baseline was determined using one of the following: generalized anxiety disorder current, panic disorder current, social anxiety disorder current, posttraumatic stress disorder current, or obsessive-compulsive disorder current based on the MINI, or having screening and baseline GAD-7 total score ≥ 10 (for TRANSFORM-1/ TRANSFORM-2 only). The primary efficacy endpoint in the TRANSFORM studies-change from baseline to endpoint (day 28) in MADRS total score-was analyzed by sex using a mixedeffects model for repeated measures (MMRM). The model included baseline MADRS total score as a covariate, and treatment, study (TRANSFORM-1/TRANSFORM-2 only), region, oral antidepressant class (SNRI or SSRI), day, sex, day-by-treatment, treatment-by-sex, and day-by-treatmentby-sex interaction as fixed effects, and a random patient effect. Changes in SDS and PHQ-9 were analyzed using the MMRM model described for the primary efficacy endpoint, but using the respective baseline score (SDS, PHQ-9) as covariate. Change in GAD-7 was analyzed using analysis of covariance with baseline GAD-7 as a covariate and treatment, region, oral antidepressant class, sex, and treatmentby-sex as factors. Response rate (defined as ≥ 50% decrease from baseline MADRS total score) and remission rate (defined as MADRS ≤ 12) at day 28 were analyzed by treatment group and sex using the generalized Cochran-Mantel-Haenszel (CMH) test. Response rate was also evaluated by menopausal status and by use of sex hormones, yes or no) among women. In other analyses, frequency distributions were provided by treatment group and sex for adverse events as a measure of safety.
Across the TRANSFORM trials, 711 patients were randomized to treatment, 6 of whom did not receive intranasal study drug and 3 additional patients did not receive either study drug. Thus, efficacy and safety were evaluated in 702 patients (464 [66.1%] women and 238 [33.9%] men) and 705 patients, respectively. Most randomized patients (women: 427/471, 90.7%; men: 207/240, 86.3%) completed doubleblind treatment. Within each of the TRANSFORM studies, women and men were similar, in general, with respect to demographic and baseline clinical characteristics (Table). Per protocol, patients in TRANSFORM-3 were older (≥ 65 years). Approximately half of women in the TRANSFORM-1 and TRANSFORM-2 studies reported being pre-menopausal (182/379, 48.0%). Of note, in the TRANSFORM-1/2 studies, the mean age at MDD diagnosis (32.8 and 31.2 years old, respectively) and mean duration of the current episodewere similar between women and men. In TRANSFORM-3, women received an MDD diagnosis at an earlier age (41.6 vs. 45.6 years old for men) and had a shorter current episode of MDD (188.6 vs. 260.3 weeks for men). The majority (71.5%) of patients in the TRANS-FORM-1/2 studies had comorbid anxiety symptoms at baseline, with no difference in prevalence between sexes (Table). Among the common medical comorbidities reported were hypertension, cardiovascular disease, diabetes, and thyroid disease. The prevalence of hypertension was balanced between sexes, whereas cardiovascular disease and diabetes were more common in older men than older women, and thyroid disease was more common in both older and younger women than men. Of note, when we refer to younger women, here and elsewhere, we are referring to those enrolled in the TRANSFORM-1/2 studies (who were 18-64 years) and older women were those enrolled in TRANSFORM-3 (who were 65 years and older). Usage of concomitant medications, which was in line with these comorbidities, was generally balanced between treatment groups among women and men, with the exception of higher levothyroxine usage by women (Table). In the TRANS-FORM-1/2 studies, hormonal therapy (including HRT and OCs) was taken by 34.8% and 21.4% of pre-menopausal women in the esketamine/antidepressant and antidepressant/placebo groups respectively, 40% and 22.2% of perimenopausal women, and 3.7% and 6.2% of post-menopausal women in the respective treatment groups. Hormonal therapy use by women in TRANSFORM-3 was uncommon (Table). Mean MADRS total score decreased from baseline to day 28, with greater improvement among those treated with esketamine/antidepressant compared to antidepressant/ placebo among both women and men. The mean MADRS change (SD) at day 28 for the esketamine/antidepressant and antidepressant/placebo groups, respectively, among the women and -18.3 (14.08) vs. -16.0 (14.30), respectively, among the men in TRANS-FORM-1/TRANSFORM-2; and -9.9 (13.34) vs. -6.9 (9.65), respectively, among the women and -10.3 (11.96) vs. -5.5 (7.64), respectively, among the men in TRANSFORM-3 (Table). The analysis failed to show any significant sex effect or treatment-by-sex interaction (p > 0.35). In the TRANSFORM trials, the proportions of patients who were responders at day 28 and the proportion of patients in remission at day 28 were numerically higher among both women and men treated with esketamine/antidepressant as compared to antidepressant/placebo (Fig.). In TRANS-FORM-3, the remission rate, but not response rate, was numerically higher among the older women compared to their male counterparts. In TRANSFORM-1/TRANS-FORM-2, pre-menopausal and post-menopausal women treated with esketamine achieved similar response rates, and the same between treatment group trend was observed for response rate among the pre-menopausal and post-menopausal women (Fig.). In the cohort of peri-menopausal women (n = 25), response rate with esketamine/antidepressant was numerically lower than among pre-menopausal and post-menopausal women. In the TRANSFORM-1/2 studies, use of hormonal therapy (HRT or OCs) had an impact on response rate at day 28 in the antidepressant/placebo arm (hormone users: 73.7% [14/19]; hormone non-users: 40.3% [48/119]), but not in the esketamine/antidepressant arm (hormone users: 54.2% [28/48]; hormone non-users: 62.3% [104/167]). Treatment benefit of esketamine was also observed in terms of functioning and self-reported depression for both women and men in the pooled TRANSFORM-1/TRANS-FORM-2 trials (Table, Fig.). The analysis for SDS and PHQ-9 failed to show any significant sex effect or treatment-by sex-interaction (p > 0.20). For GAD-7, there was no treatment-by-sex interaction (p > 0.52); however, the sex effect trended towards significance (p = 0.07; i.e., women showed greater change from baseline than men, regardless of treatment). The most common adverse events (incidence > 20%) reported for esketamine/antidepressant were nausea, dissociation, dizziness, and vertigo (Table). Among esketamine-treated patients, the incidences of nausea and dissociation were higher among women than among men, regardless of age. The incidences of vertigo and dizziness were numerically higher and lower, respectively, among the younger women vs. younger men in the TRANSFORM-1/ TRANSFORM-2 studies; the opposite by-sex trend for incidences of these events was observed among the older patients in TRANSFORM-3. While reported at a lower incidence overall (i.e., 9.3%), the incidence of increased blood pressure was numerically higher among younger men (12.8%) and older women (17.8%), than their counterparts. Overall, most adverse events occurred on nasal spray dosing days, were mild or moderate in severity, resolved the same day, and were generally not treatment limiting. With regard to dissociation events, their median duration ranged from 0.7 to 1 h across dosing sessions (within the post-dose observation period), a minority (3.1%) of events were classified as severe, and none were considered serious. A serious adverse event was reported during treatment with esketamine for two (0.7%) women (single events of depression and anxiety disorder) and four (2.9%) men (single events of headache, hip fracture, increased blood pressure, and multiple injuries/road traffic accident [the latter event occurred on day 16 and was considered doubtfully related to esketamine or to antidepressant; patient subsequently died on day 55]). A minority of patients discontinued intranasal study drug due to adverse events in the TRANSFORM studies (esketamine: 20/415, 4.8%; placebo: 5/287, 1.7%). Among esketamine-treated patients, 12 women discontinued study drug prematurely, due to multiple events in some cases (5 events of increased systolic blood pressure and 1 event of anxiety disorder for 1 older patient each in TRANSFORM-3; 3 events each of dizziness and nausea, 2 events each of depression, headache, and vomiting, and single events of anxiety, disturbance in attention, drug intolerance, extrasystoles, feeling drunk, motion sickness, tachycardia, and vertigo for younger patients in TRANSFORM-1/TRANSFORM-2) and 8 men discontinued study drug prematurely (single events of hip fracture and increased blood pressure for 1 older patient each Abbreviations: CGI-S Clinical Global Impression-Severity; MDD major depressive disorder; NA not applicable or not available, not administered; PHQ Patient Health Questionnaire; SNRI serotonin and norepinephrine reuptake inhibitor; SSRI selective serotonin reuptake inhibitor; TRD treatment-resistant depression a Data from the Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire, Module I, in the TRANSFORM-1 and TRANSFORM-2 studies b Any type of employment includes any category containing "employed," sheltered work, housewife or dependent husband, and student; any type of unemployment includes any category containing "unemployed"; other includes retired and no information available c In accordance with the trial protocols, patients entering the induction phase had non-response to at least 2 oral antidepressant medications prior to randomization. The data presented is the number of antidepressant medications with non-response (defined as ≤ 25% improvement) taken for at least 6 weeks during the current episode d Ns for the previous antidepressant medications in TRANSFORM-1/TRANSFORM-2 are 377, 186, and 563 for women, men, and total patients, respectively e Assigned by the investigator at randomization Odds ratio = odds of achieving response on esketamine + antidepressant divided by the odds of achieving response on antidepressant + placebo in TRANSFORM-3; 2 events of panic attack and single events of anxiety, depressive symptoms, mania, and multiple injuries/road traffic accident for younger patients in TRANSFORM-1/TRANSFORM-2).
Similar and robust improvement of depressive symptoms from baseline was observed with esketamine nasal spray compared to placebo nasal spray, in conjunction with an oral antidepressant, among both women and men with TRD. While the between-group difference observed with esketamine/antidepressant vs. antidepressant/placebo was numerically higher among women than men in TRANS-FORM-1/TRANSFORM-2 (LS means (SE) -4.5 (1.41) 95% CI -7.26, -1.70 for women vs. -1.6 (2.04) 95% CI -5.60, 2.41 for men) and vice versa in TRANSFORM-3 (LS means (SE) -3.4 (2.41) 95% CI -8.14, 1.41 for women vs. -5.0 (3.05) 95% CI -11.05, 1.03 for men), the treatment-by-sex interaction was not statistically significant (p > 0.35) and the 95% CIs for the differences overlap. Furthermore, the betweengroup difference observed vs. antidepressant/placebo for both sex subgroups in TRANSFORM-1/TRANSFORM-2 and TRANSFORM-3 was in the range considered clinically meaningful (2-point to 3-point difference)) and is consistent with that observed in clinical trials of the most recently approved biogenic amine antidepressants compared with only a placebo rather than an active comparator). The proportions of patients who were responders at day 28 and the proportion of patients in remission at day 28 were numerically higher among both women and men treated with esketamine/antidepressant as compared to antidepressant/placebo. While it is noted that the remission rate, but not response rate, was numerically higher among the older women, compared to the older men in TRANSFORM-3, the small cohort sizes limit a conclusion being made from the comparison. Additionally, as noted in the "Materials and methods" section, the TRANSFORM-3 study, unlike TRANSFORM-1 and 2, included a lower 28 mg dose and post hoc analyses of TRANSFORM-3 dataMean (SD) change from baseline to day 28 for SDS, PHQ-9, and GAD-7 total score in pooled TRANSFORM-1/ TRANSFORM-2 trials SDS total score ranges from 0 to 30; a higher score indicates greater impairment. PHQ-9 total score ranges from 0 to 27; a higher score indicates greater depression. GAD-7 total score ranges from 0 to 21; a higher score indicates more anxiety. Negative change in SDS total score, PHQ-9 total score, and GAD-7 total score indicates improvement for each GAD-7 Generalized Anxiety Disorder 7-item; LS least squares; PHQ-9 Patient Health Questionnaire 9-item; SD standard deviation; SDS Sheehan Disability Scale revealed several factors that potentially contributed to its failure to achieve statistical significance on the primary endpoint. The treatment benefit of esketamine, regardless of sex, was also observed based on the patient-reported outcomes of functioning (SDS total score), severity of anxiety (GAD-7 total score), and depressive symptoms (PHQ-9 total). The absence of evidence of sex-based differences may be explained, in part, by the absence of differences in the pharmacokinetics of esketamine between male and female subjects (Spravato TM Prescribing Information 2020). Sex differences in efficacy outcomes have been reported for other antidepressants, although findings have been inconsistent. In some studies, older men responded better to tricyclic antidepressants than women, and in other studies women responded better to SSRIs, and to a lesser extent SNRIs, than men. Alternatively, other studies have reported no sex-based differences in antidepressant efficacy. Differences in study design (prospective, retrospective, meta-analysis), patient selection criteria (e.g., age of patients, clinical presentation, severity/duration of depression), study drug (mechanism of action, dosage, duration of treatment), and response criteria may explain the inconsistency in these findings across studies. As noted in the "Introduction" section, findings regarding the effect of menopausal status on response to antidepressants have also been mixed, with some research groups reporting greater response among women treated with an SSRI vs. a tricyclic antidepressant, driven by between-group differences in premenopausal women, and not in those who were post-menopausal. In a pooled analysis of data from 8 randomized, controlled trials, older women exhibited lower remission rates on SSRI than younger women, a trend that was reversed for those taking hormone replacement therapy; remission rates were higher for women treated with SNRI, irrespective of age and hormone replacement therapy. Although small sample size precluded analysis of efficacy by concomitant oral antidepressant class (SSRI, SNRI), by sex or menopausal status, oral antidepressant class was included in the MMRM as a fixed effect. With esketamine, while the response rate with esketamine/antidepressant was numerically lower in the small sample of peri-menopausal women (n = 24), it appears that post-menopausal women with TRD achieve the same benefit that pre-menopausal women do. These findings are consistent with those of, who found no difference between women and men treated with intravenous ketamine for rapid reduction of depressive symptoms, with no difference observed based on menopause status, suggesting antidepressants with a glutamatergic mechanism of action, unlike biogenic amines, may not be impacted by the reproductive life cycle of women. In the TRANSFORM-1/2 studies, use of hormonal therapy increased response rate at day 28 in the antidepressant/ placebo arm, but not in the esketamine/antidepressant arm. Others have also observed that hormone therapy impacts response among women receiving SSRI or SNRI. The most common adverse events experienced by esketamine-treated patients were dissociation, headache, nausea (each reported at a rate higher in women than men), dizziness (reported at a rate higher in older women than older men [in TRANSFORM-3]), and vertigo (reported at a rate higher in younger women than younger men [in TRANS-FORM-1/TRANSFORM-2]). Increased blood pressure was reported most often among older women. This trend is in line with the higher risk for women having adverse drug reactions, in general, and for specific types of events during treatment with antidepressants (e.g., weight gain with SSRIs). Fig.Difference in least square means for SDS, PHQ-9, and GAD-7 total score by sex in pooled TRANSFORM-1/TRANSFORM-2 trials. CI = confidence interval; GAD-7 = Generalized Anxiety Disorder 7-item; LS = least squares; PHQ-9 = Patient Health Questionnaire 9-item; SDS = Sheehan Disability Scale. Notes: SDS total score ranges from 0 to 30; a higher score indicates greater impairment. PHQ-9 total score ranges from 0 to 27; a higher score indicates greater depression. GAD-7 total score ranges from 0 to 21; a higher score indicates more anxiety. Negative change in SDS total score, PHQ-9 total score, and GAD-7 total score indicates improvement for each, and a negative difference favors esketamine
The strengths of this post hoc analysis include the relatively large numbers of participants, the active-controlled design, validated diagnostic assessments for comorbid psychiatric disorders, and the systematic ascertainment of menopausal status and other sex-specific data. Our findings are limited by the fact that patients were not stratified into the TRANSFORM studies based on sex, although the higher participation by women (66.1% overall) was similar across the TRANSFORM studies and is consistent with the well-known sex disparity in the prevalence of major depression worldwide. We note that the results of analyses by menopausal status must be interpreted with caution given small sample sizes. Similarly, sub-analyses from TRANSFORM-3 (patients 65 years and older) should also be interpreted with caution due to the small sample size and differences in dosing regimen (including a lower 28 mg dose, in addition to 56 mg and 84 mg). Other limitations to the generalizability of findings from the current post hoc analysis include exclusion of patients with some common psychiatric and medical comorbidities and low participation by non-white patients.
These analyses support antidepressant efficacy and safety of esketamine nasal spray for women with TRD, without notable differential effects based on sex. These findings add to the existing literature and support data-informed decisionmaking for women with TRD. TableMost frequently reported treatment-emergent adverse events in the double-blind treatment phase of short-term randomized, controlled TRD trials by sex and treatment group The table lists, in descending order of frequency for all patients, all adverse events with an incidence ≥ 10% in any esketamine group AE adverse event, BP blood pressure, UTI urinary tract infection
Create a free account to open full-text PDFs.
Randomized, double-blind, active-controlled Phase III study (n=346) comparing fixed-dose intranasal esketamine (56 mg or 84 mg) plus a newly initiated oral antidepressant versus intranasal placebo plus a newly initiated oral antidepressant in adults with treatment-resistant depression.
Papers cited by this study that are also in Blossom
Chen, X., Hou, X., Bai, D. et al. · American Journal of Psychiatry (2023)
Papers in Blossom that reference this study
Ammendolia, I., Mannucci, C., Esposito, E. et al. · Pharmaceuticals (2025)